Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

B-cell depleting therapies are highly efficacious in relapsing-remitting multiple sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no phase 3 trial data are available. We therefore examined the safety and efficacy of rituximab compared with dimethyl fumarate in p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2022, Vol.21 (8), p.693-703
Hauptverfasser:	Svenningsson, Anders, Frisell, Thomas, Burman, Joachim, Salzer, Jonatan, Fink, Katharina, Hallberg, Susanna, Hambraeus, Joakim, Axelsson, Markus, Nimer, Faiez Al, Sundström, Peter, Gunnarsson, Martin, Johansson, Rune, Mellergård, Johan, Rosenstein, Igal, Ayad, Ahmad, Sjöblom, Irina, Risedal, Anette, de Flon, Pierre, Gilland, Eric, Lindeberg, Jonas, Shawket, Fadi, Piehl, Fredrik, Lycke, Jan
Format:	Artikel
Sprache:	eng
Schlagworte:	Copolymer 1 Drug dosages fingolimod Immunotherapy Interferon interferon beta-1a Intravenous administration Lymphocytes B Monoclonal antibodies multicenter Multiple sclerosis Neurosciences Neurosciences & Neurology Neurovetenskaper oral bg-12 Patients placebo-controlled phase-3 Rituximab Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!